Shots: Avidity to receive $20M upfront, $15M equity investment, $405M as development, regulatory & commercial milestones for each target and royalties on sales. Lilly to get WW rights to develop […]readmore
Tags : Agreement
Shots: Black Belt to get $5.64M (€5M) upfront, equity investment of $2.26M (€2M), milestones and royalties on sales. CASI to get exclusive WW rights to develop and commercialize Black Belt’s […]readmore
Shots: Moleculin collaborated with Emory University to conduct P-I trial for WP1066 to treat recurrent or refractory malignant brain tumors in pediatric patients The trial will be conducted at Aflac […]readmore
Shots: Indivumed to receive upfront from Evotec, for accessing Indivumed’s database “IndivuType” and both companies will jointly invest in data analysis, target identification, validation, and drug discovery. Evotec will be […]readmore
Shots: Shionogi to receive $30M upfront ($20M as initial payment & additional $10M in 6mos.) and royalties based on the sales of Symproic. BDSI to get exclusive commercialization rights for […]readmore
Shots: Cognoa to get exclusive license rights for Stanford’s Google Glass-based autism technology to develop & commercialize digital therapies for children with autism spectrum disorder (ASD) The Superpower Glass (SG) […]readmore
Shots: Synaffix to receive upfront and milestones leading to total deal value $125M and royalties on sales of product. Miracogen to get non-exclusive license rights for Synaffix’s GlycoConnect and HydraSpace […]readmore
Shots: ReNeuron to receive £6.0M ($7.9M) upfront, £6.0M ($7.9M) near-term milestones, £8.0M ($10.5M) regulatory milestones and post-launch profit threshold milestones of 5% on annual profit, leading to total milestones £80.0M […]readmore
Shots: Xinhua Healthcare to get exclusive license rights to commercialize ArcDia’s mariPOC platform in China. ArcDia to supply biochemical assay components and R&D services to Xinhua The focus of the […]readmore
Shots: BioAtla to receive $20M upfront, $249M as WW development & regulatory milestones, commercial milestones and royalties in Beigene’s territory (Asia (ex-Japan), Australia and New Zealand). Beigene to get WW […]readmore